Alkermes (ALKS) – Analysts’ Recent Ratings Updates

Alkermes (NASDAQ: ALKS) recently received a number of ratings updates from brokerages and research firms:

• 11/1/2025 – Alkermes was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 10/29/2025 – Alkermes had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $42.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Alkermes had its price target raised by analysts at Needham & Company LLC from $43.00 to $44.00. They now have a “buy” rating on the stock.
• 10/28/2025 – Alkermes was given a new $56.00 price target on by analysts at Jefferies Financial Group Inc.. They now have a “buy” rating on the stock.
• 10/27/2025 – Alkermes had its price target raised by analysts at Mizuho from $40.00 to $45.00. They now have an “outperform” rating on the stock.
• 10/23/2025 – Alkermes had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $45.00 price target on the stock, up previously from $38.00.
• 10/22/2025 – Alkermes had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $47.00. They now have an “outperform” rating on the stock.
• 10/22/2025 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 10/22/2025 – Alkermes was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/14/2025 – Alkermes had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Alkermes had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Alkermes was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating. They now have a $44.00 price target on the stock, up previously from $42.00.
• 9/9/2025 – Alkermes was given a new $43.00 price target on by analysts at Needham & Company LLC.
• 9/9/2025 – Alkermes had its price target raised by analysts at JPMorgan Chase & Co. from $34.00 to $35.00. They now have a “neutral” rating on the stock.
• 9/9/2025 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.

Insiders Place Their Bets

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $30.38, for a total transaction of $273,420.00. Following the transaction, the executive vice president owned 69,740 shares in the company, valued at $2,118,701.20. The trade was a 11.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.40% of the stock is owned by company insiders.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.